About Bellerophon Therapeutics
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication. Its INOpulse device has a mechanism that delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs, which minimizes the amount of drug required for treatment. The Company's second program, BCM, is a medical device focused to prevent congestive heart failure following a ST Segment Elevation Myocardial Infarction (STEMI), which is a type of severe heart attack. The Company's BCM is in PRESERVATION I clinical trial.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: BLPH
- Previous Close: $1.40
- 50 Day Moving Average: $0.780
- 200 Day Moving Average: $1.047
- 52-Week Range: $0.43 - $4.58
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.32
- P/E Growth: 0.000
- Market Cap: $18.84M
- Outstanding Shares: 14,506,000
- Beta: -2.64
- Return on Equity: -117.99%
- Return on Assets: -91.74%
Companies Related to Bellerophon Therapeutics:
- Current Ratio: 3.67%
- Quick Ratio: 3.67%
What is Bellerophon Therapeutics' stock symbol?
Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."
Where is Bellerophon Therapeutics' stock going? Where will Bellerophon Therapeutics' stock price be in 2017?
4 analysts have issued 1-year price targets for Bellerophon Therapeutics' shares. Their forecasts range from $5.00 to $12.00. On average, they anticipate Bellerophon Therapeutics' stock price to reach $9.25 in the next year.
When will Bellerophon Therapeutics announce their earnings?
Bellerophon Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 20th 2017.
Who owns Bellerophon Therapeutics stock?
Bellerophon Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Boxer Capital LLC (12.80%), FMR LLC (8.33%), Armistice Capital LLC (6.89%) and Renaissance Technologies LLC (1.65%). Company insiders that own Bellerophon Therapeutics stock include Jens Luehring and Jonathan M Peacock.
Who bought Bellerophon Therapeutics stock? Who is buying Bellerophon Therapeutics stock?
Bellerophon Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Boxer Capital LLC, Armistice Capital LLC and Renaissance Technologies LLC. Company insiders that have bought Bellerophon Therapeutics stock in the last two years include Jens Luehring and Jonathan M Peacock.
How do I buy Bellerophon Therapeutics stock?
Shares of Bellerophon Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Bellerophon Therapeutics stock cost?
One share of Bellerophon Therapeutics stock can currently be purchased for approximately $1.29.